Introduction
The swine industry in China currently faces a dual challenge from emerging variants of Porcine Epidemic Diarrhea Virus (PEDV) and Pseudorabies Virus (PRV). These variants have significantly reduced the efficacy of traditional vaccines, such as CV777 and Bartha K61, leading to substantial economic losses. To address this, researchers have turned to viral vector technology. A previously developed gene-deleted PRV strain (PRV TK&gE-AH02) has shown promise as a safe and effective live vaccine vector. By using this vector to express the Spike (S) protein of PEDV variants, scientists aim to create multivalent vaccines. However, a critical hurdle in vector design is determining the optimal genomic insertion site that maximizes foreign gene expression without compromising the virus's replication or stability.
Methodology
This study systematically evaluated four noncoding regions within the PRV genome as potential "parking spots" for the PEDV S gene expression cassette: UL11-10, UL35-36, UL46-27, and US2-1.
The researchers utilized Bacterial Artificial Chromosomes (BACs) to clone the ~145 kb PRV genome, enabling precise genetic editing via En Passant Mutagenesis. This two-step, markerless recombination method allowed for the insertion of the S gene into the four specific sites. Following construction, the recombinant viruses were "rescued" by transfecting the modified DNA into mammalian cells. The team then employed RT-qPCR to quantify mRNA expression, Indirect Immunofluorescence Assays (IFA) to confirm protein production, and multi-step growth curves in Swine Testicular (ST) cells to assess viral fitness.
Results
The study revealed that genomic location significantly influences both the viability and the expression efficiency of the recombinant virus.
Viability and Stability
While insertions at UL11-10, UL35-36, and UL46-27 yielded viable recombinant viruses, the US2-1 site proved lethal. Recombinants with the S gene at US2-1 could not be rescued, indicating that this region is essential for the replication of the AH02LA PRV variant. For the successful recombinants, the S gene remained stable within the PRV genome for at least 20 passages in cell culture, meeting a key requirement for commercial vaccine production.
Expression Levels
Quantitative analysis showed distinct differences in antigen production:
- 6 Hours Post-Infection (hpi): Both PRV-S(UL11-10) and PRV-S(UL35-36) exhibited significantly higher S gene mRNA levels compared to PRV-S(UL46-27) (P < 0.05).
- 12 Hours Post-Infection (hpi): The UL11-10 site emerged as the top performer, showing higher expression than UL35-36 (P = 0.097) and significantly higher expression than UL46-27 (P < 0.05).
Viral Fitness
Importantly, the insertion of the large S gene cassette did not hinder the virus's ability to replicate. The growth kinetics of the three successful recombinants were nearly identical to the parental attenuated strain, reaching peak titers between $10^{7.87}$ and $10^{8.27}$ $TCID_{50}/mL$.
Discussion and Future Directions
The identification of the UL11-10 noncoding region as the optimal insertion site provides a clear roadmap for developing more potent recombinant PRV vaccines. By maximizing antigen expression while maintaining viral fitness, this site offers the best potential for inducing a strong immune response.
However, several questions remain. The failure of the US2-1 site suggests unique biological constraints in the AH02LA variant that require further investigation. Furthermore, while these in vitro results in ST cells are promising, the next phase of research must involve in vivo trials in piglets. These trials will determine if the superior expression at the UL11-10 site translates into enhanced clinical protection against both PEDV and PRV in a farm setting.
Summary updated